Eli Lilly and Company (NYSE:LLY) Shares Sold by Foster & Motley Inc.

Foster & Motley Inc. reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 945 shares of the company’s stock after selling 63 shares during the quarter. Foster & Motley Inc.’s holdings in Eli Lilly and Company were worth $551,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $26,000. Thompson Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at about $27,000. Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company during the third quarter worth about $35,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company during the third quarter worth about $36,000. Finally, Family CFO Inc acquired a new position in Eli Lilly and Company in the 3rd quarter valued at about $40,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Down 1.8 %

Shares of NYSE LLY opened at $732.20 on Thursday. The firm’s 50-day moving average is $763.40 and its two-hundred day moving average is $664.52. The company has a market capitalization of $695.71 billion, a PE ratio of 126.24, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $370.68 and a 12-month high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.09 EPS. Equities analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. BMO Capital Markets increased their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald restated an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a research report on Monday, April 15th. The Goldman Sachs Group raised their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Finally, Morgan Stanley boosted their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.